Given the ability of IL-10 to potentiate the efficacy of PD-1 blockade in NSCLC,28 we then reasoned that the greater capacity of intestinal mononuclear phagocytes to secrete the immunosuppressive IL-10 cytokine in response to CBM588 may probably contribute to the greater responsiveness to anti-PD1 antibodies. The gene discussed is IL10; the disease is non-small cell lung carcinoma.